Investigating the hepatitis B virus capsid to find new antiviral treatments
Official title: Molecular dynamics of the HBV capsid to advance the search for antivirals
Funded at University of Delaware · NIH-11185622 · Data updated 2026-11-12
This study is looking at a part of the hepatitis B virus to find new ways to stop it from growing, which could lead to better treatments for people living with hepatitis B.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Delaware NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | September 5, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $175,873 |
| NIH project number | 5P20GM104316-10 |
| Project ID | NIH-11185622 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic hepatitis B virus infections who are seeking new treatment options.
✕Less likely to help
Patients with hepatitis C or other unrelated viral infections may not benefit from this research.
What this research studies
This research focuses on the hepatitis B virus (HBV) capsid, which is a potential target for new antiviral therapies. The project utilizes advanced computational techniques, specifically molecular dynamics simulations, to explore the various conformations of the capsid proteins. By identifying small molecules that can disrupt the assembly of the capsid, the research aims to develop effective inhibitors that could lead to new treatments for HBV. Patients may benefit from this work as it seeks to advance the development of antiviral drugs that could eliminate viral hepatitis.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiviral drugs that effectively treat hepatitis B virus infections.
How similar studies have gone: While the approach of targeting the HBV capsid is promising, it is relatively novel and has not yet been widely tested in clinical settings.
Where this research is happening
-
University of Delaware
Newark, United States Active
Researchers
- Principal investigator: Hadden-Perilla, Jodi a — University of Delaware
- Study coordinator: Hadden-Perilla, Jodi a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.